Ketamine as a Supplement to Local Anesthesia for Minor Procedures
Intranasal Ketamine as a Supplement to Local Anesthesia to Reduce Pain Associated With Minor Procedures in the Emergency Department
Loyola University
108 participants
May 25, 2022
INTERVENTIONAL
Conditions
Summary
This trial is a double-blind randomized controlled clinical trial of adults and children (ages 7 to less than 70 years). Patients who present to the ED and who undergo minor bedside procedures that require local anesthesia will be divided into two groups: The first group will be treated with 0.7 mg/kg intranasal ketamine as well as standard local anesthesia for the procedure (treatment cohort). The second group will be treated with a volume-based dose of intranasal saline solution as well as standard local anesthesia for the procedure (control cohort). The primary aim is to assess whether patients in the treatment cohort report lower pain scores on the Numerical Rating Scale (NRS-100) when compared to patients in the control cohort. For adult patients, a secondary aim is to compare agitation between the two cohorts using the Richmond Agitation Sedation Scale (RASS) and, for pediatric patients, a secondary aim is to compare alertness between the two cohorts using the University of Michigan Sedation Scale (UMSS). Results obtained from specific procedures will be analyzed on a spectrum of complexity and general length of recovery time. Scientific achievements may include finding a safe and effective way to reduce pain and discomfort during minor procedures in the Emergency Department. Additionally, it would provide opportunities for more research on sub-dissociative doses of ketamine during minor procedures: a topic in which there is still a gap in the published research
Eligibility
Inclusion Criteria2
- Undergoing Minor Procedure in the ED
- Weight not to exceed 115kg
Exclusion Criteria12
- Altered Mental Status
- Pregnancy
- Breastfeeding
- Acute head or eye injury
- Intercranial Hypertension
- Hx of seizures
- Hx of chronic pain
- Unstable vital signs
- Allergy to Ketamine
- Hepatic or Renal Insufficiency
- Hx of Psychiatric Illness
- Hx of alcohol/drug abuse
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Ketamine is an N-methyl-D aspartate receptor agonist
Intranasal saline flushes pollen, dust, and other debris from nasal passages. It also removes excess mucus and adds moisture
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06284473